Adenovirus SARS-CoV-2 Vaccine
AssigneeThe Wistar Institute
InventorHildegund C.J. Ertl
Life of this patent
Estimating the term…
Abstract
The present invention includes methods and compositions useful for treating or preventing a coronavirus infection in a subject. In certain embodiments the treatment comprises adenoviral-based vaccines against SARS-CoV-2 viral proteins.
Claims40
An immunogenic composition comprising an effective amount of a first adenoviral vector comprising a first nucleotide sequence encoding a first SARS-CoV-2 protein and a second adenoviral vector comprising a second nucleotide sequence encoding a second SARS-CoV-2 protein.
A viral vector comprising a first nucleotide sequence encoding a first SARS-CoV-2 protein and a second nucleotide sequence encoding a second SARS-CoV-2 protein.
A method of stimulating an immune response in a subject, the method comprising administering to the subject:
- (i) an effective amount of a first adenoviral vector comprising a first nucleotide sequence encoding a first SARS-CoV-2 protein;
- and (ii) a second adenoviral vector comprising a second nucleotide sequence encoding a second SARS-CoV-2 protein.
A method for treating or preventing a coronavirus infection in a subject, the method comprising administering to the subject:
- (i) an effective amount of a first adenoviral vector comprising a first nucleotide sequence encoding a first SARS-CoV-2 protein;
- and (ii) a second adenoviral vector comprising a second nucleotide sequence encoding a second SARS-CoV-2 protein.
Dependencies are inferred from the claim text.